These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27091466)

  • 1. Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study.
    Myklebust M; Gjengedal E; Strømsvik N
    J Genet Couns; 2016 Dec; 25(6):1198-1206. PubMed ID: 27091466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
    Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
    Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproductive decision-making in young female carriers of a BRCA mutation.
    Donnelly LS; Watson M; Moynihan C; Bancroft E; Evans DG; Eeles R; Lavery S; Ormondroyd E
    Hum Reprod; 2013 Apr; 28(4):1006-12. PubMed ID: 23293217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptation of couples living with a high risk of breast/ovarian cancer and the association with risk-reducing surgery.
    Shapira R; Turbitt E; Erby LH; Biesecker BB; Klein WMP; Hooker GW
    Fam Cancer; 2018 Oct; 17(4):485-493. PubMed ID: 29209897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    Kotsopoulos J; Gronwald J; Karlan B; Rosen B; Huzarski T; Moller P; Lynch HT; Singer CF; Senter L; Neuhausen SL; Tung N; Eisen A; Foulkes WD; Ainsworth P; Sun P; Lubinski J; Narod SA;
    Gynecol Oncol; 2018 Jul; 150(1):85-91. PubMed ID: 29793803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
    Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
    Kautz-Freimuth S; Redaèlli M; Rhiem K; Vodermaier A; Krassuski L; Nicolai K; Schnepper M; Kuboth V; Dick J; Vennedey V; Wiedemann R; Schmutzler R; Stock S
    BMC Med Inform Decis Mak; 2021 Jun; 21(1):180. PubMed ID: 34090422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management updates for women with a BRCA1 or BRCA2 mutation.
    Nusbaum R; Isaacs C
    Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
    DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
    Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.